2017
DOI: 10.18632/oncotarget.23229
|View full text |Cite
|
Sign up to set email alerts
|

Global view of a drug-sensitivity gene network

Abstract: An important challenge in drug development is to gain insight into the mechanism of drug sensitivity. Looking for insights into the global relationships between drugs and their sensitivity genes would be expected to reveal mechanism of drug sensitivity. Here we constructed a drug-sensitivity gene network (DSGN) based on the relationships between drugs and their sensitivity genes, using drug screened genomic data from the NCI-60 cell line panel, including 181 drugs and 1057 sensitivity genes, and 1646 associati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 46 publications
0
1
0
Order By: Relevance
“…Once basic cellular interactome maps have been created for enough microbes, and 3D models of enough enzymes of key metabolic processes have been elucidated, prediction of interaction surfaces will become routine and automated (e.g., see Meyer et al, 2018). Such surfaces will constitute new drug targets for interruption of essential metabolic functions in pathogenic microbes (e.g., Zoraghi and Reiner, 2013;Li et al, 2018;Llano and Peña-Hernandez, 2018;Yang et al, 2018). Contemporary efforts to inventarize microbial diversity (Venter et al, 2004;Alivisatos et al, 2015;Salazar et al, 2016;Thompson et al, 2017) will eventually lead to the availability of representative genome sequences of much of microbial diversity.…”
Section: Ligandomics 20: Sequence-guided Automated Drug Design and Smentioning
confidence: 99%
“…Once basic cellular interactome maps have been created for enough microbes, and 3D models of enough enzymes of key metabolic processes have been elucidated, prediction of interaction surfaces will become routine and automated (e.g., see Meyer et al, 2018). Such surfaces will constitute new drug targets for interruption of essential metabolic functions in pathogenic microbes (e.g., Zoraghi and Reiner, 2013;Li et al, 2018;Llano and Peña-Hernandez, 2018;Yang et al, 2018). Contemporary efforts to inventarize microbial diversity (Venter et al, 2004;Alivisatos et al, 2015;Salazar et al, 2016;Thompson et al, 2017) will eventually lead to the availability of representative genome sequences of much of microbial diversity.…”
Section: Ligandomics 20: Sequence-guided Automated Drug Design and Smentioning
confidence: 99%